What is Added to Compounded Tirzepatide
Compounded tirzepatide products commonly contain cyanocobalamin (vitamin B12), glycine, niacinamide, docusate sodium, or ondansetron in various combinations, though these additions lack evidence for safety and efficacy.
Common Additives in Compounded Formulations
Based on a comprehensive market analysis, 48% of compounded tirzepatide products contain the active ingredient combined with some mixture of the following substances 1:
- Cyanocobalamin (Vitamin B12) - most common additive
- Glycine - amino acid
- Niacinamide - vitamin B3 derivative
- Docusate sodium - stool softener
- Ondansetron - anti-nausea medication
The remaining products (52%) contain tirzepatide as a single active ingredient but are formulated as sublingual preparations (82%) or oral disintegrating tablets (18%) rather than the FDA-approved subcutaneous injection 1.
Critical Safety Concerns
Chemical Impurity Formation
A novel and widespread impurity has been identified in compounded tirzepatide/B12 combination products, resulting from a chemical reaction between tirzepatide and certain vitamin B12 analogs 2. This impurity:
- Is present at substantial levels
- Has unknown clinical effects
- Was previously unidentified
- Exists despite products being marketed as "personalized" treatments
Lack of Scientific Justification
There is little to no justification for adding these substances to tirzepatide 1:
- Nutrients (B12, glycine, niacinamide): No evidence supports combining these with subcutaneous tirzepatide
- Docusate sodium: No rationale for inclusion in injectable formulations
- Ondansetron: While there is theoretical rationale for anti-nausea effects, evidence for subcutaneous co-administration is lacking
Quality and Storage Issues
Compounded products demonstrate poor quality control:
- Only 18% report beyond-use dates
- Only 28% report preferred storage conditions 1
- No FDA evaluation of potency or impurity profiles 2
Clinical Implications
The popularity of these compounded alternatives is concerning given the complete absence of safety and efficacy data 1. These products are mass-marketed as comparable to FDA-approved tirzepatide despite undergoing no regulatory evaluation, highlighting risks inherent in marketing complex therapies outside the drug-approval framework 2.